Cited 0 times in
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2023-03-21T07:31:11Z | - |
dc.date.available | 2023-03-21T07:31:11Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 2152-2650 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193417 | - |
dc.description.abstract | Background: In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma. Patients and methods: In this predefined subgroup analysis, efficacy, and safety between East Asian patients and the overall population were assessed. Results: In total, 36 East Asian patients were included (Japanese, n = 13; Korean, n = 9; Taiwanese, n = 14). At a median follow-up of 11.6 months, median progression-free survival was not reached (95% confidence interval [CI] 5.80-not calculable) in the Isa-Pd arm and was 7.9 months (95% CI 2.90-not calculable) in the Pd arm. The hazard ratio for the between-group difference was 0.52 (95% CI 0.19-1.39), which was similar to the overall population (hazard ratio, 0.60; 95% CI 0.44-0.82). No new safety signals were observed, except that a higher proportion of patients in the East Asian population experienced Grade ≥ 3 neutropenia compared with the overall population. Conclusion: These results confirm the efficacy of Isa-Pd in East Asian patients with relapsed/refractory multiple myeloma, and the related safety data are consistent with those observed in the overall population and are manageable. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Dexamethasone / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Multiple Myeloma* / drug therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy | - |
dc.subject.MESH | Thalidomide / analogs & derivatives | - |
dc.title | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kazutaka Sunami | - |
dc.contributor.googleauthor | Takashi Ikeda | - |
dc.contributor.googleauthor | Shang-Yi Huang | - |
dc.contributor.googleauthor | Ming-Chung Wang | - |
dc.contributor.googleauthor | Youngil Koh | - |
dc.contributor.googleauthor | Chang Ki Min | - |
dc.contributor.googleauthor | Su-Peng Yeh | - |
dc.contributor.googleauthor | Morio Matsumoto | - |
dc.contributor.googleauthor | Michihiro Uchiyama | - |
dc.contributor.googleauthor | Satoshi Iyama | - |
dc.contributor.googleauthor | Chihiro Shimazaki | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Hitomi Kaneko | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Tung-Liang Lin | - |
dc.contributor.googleauthor | Frank Campana | - |
dc.contributor.googleauthor | Keisuke Tada | - |
dc.contributor.googleauthor | Shinsuke Iida | - |
dc.contributor.googleauthor | Kenshi Suzuki | - |
dc.contributor.googleauthor | ICARIA-MM study group | - |
dc.identifier.doi | 10.1016/j.clml.2022.04.005 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J04262 | - |
dc.identifier.eissn | 2152-2669 | - |
dc.identifier.pmid | 35641409 | - |
dc.subject.keyword | Efficacy and safety | - |
dc.subject.keyword | Far East | - |
dc.subject.keyword | Isa-Pd | - |
dc.subject.keyword | Japan | - |
dc.subject.keyword | RRMM | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 22 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | E751 | - |
dc.citation.endPage | E761 | - |
dc.identifier.bibliographicCitation | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol.22(8) : E751-E761, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.